Delta Diagnostics receives backing to develop biosensor system

Biosensor R&D start-up Delta Diagnostics has received a seed investment from two innovators: research organisation TNO – The Netherlands Organisation for Applied Scientific Research – and PhotonDelta, an ecosystem of photonic chip technology organisations. 

This investment enables Delta Diagnostics to further develop and validate its biosensor systems in preparation for a Series A investment round later this year.

A specialist in instrumentation for life science research and diagnostic test development, Delta Diagnostics was spun out from TNO’s optics department in 2018 after a decade of research.

Delta Diagnostic’s biosensor technology uses photonic chips to detect up to 16 biomolecules simultaneously, with an instrument that is much more affordable.

Bart de Boer, CTO and co-founder of Delta Diagnostics, has firm plans for the seed funding, saying: ‘’This investment enables us to further develop and validate our photonic biosensor system. The next step is to move from prototype to serial-producible product. We believe that our technology will ultimately result in new, more reliable, diagnostic tests that are developed at reduced time and cost.’’

Hans Boumans, director of technology transfer at TNO, added: “Delta Diagnostics is a great example of how TNO’s Technology Transfer Programme continues to accelerate market adoption. The start-up’s ambition is a prime example of an organisation successfully delivering high tech that advances society, stimulates business, and creates new jobs.”

As an ecosystem that researches, designs, develops, and manufactures solutions with integrated photonics technology, PhotonDelta provides funding to support start-ups like Delta Diagnostics.

Pieter Klinkert, fund manager at PhotonDelta, explains: “We see great opportunities for biosensing instruments based on photonic chips, as the healthcare industry needs faster and cheaper solutions to diagnose patients. That’s why it makes sense that we support Delta Diagnostics in their next steps to validate and commercialise their products.”